Quick Takeaways:
- BioTesserae, in collaboration with Sunflower Therapeutics, reported that BTC-001, a PD-1 targeting single-domain antibody, was well tolerated in healthy dogs in a single ascending dose study
- BTC-001, inspired by human immunotherapies like Opdivo and Keytruda, is designed as a simplified biologic enabling flexible treatment options and streamlined manufacturing for veterinary oncology
- The partnership leverages Sunflower’s yeast-based platform to support scalable production, advancing development of affordable, next-gen biologics for canine cancer treatment
Why It Matters?
BioTesserae’s BTC-001, a PD‑1–targeting single‑domain antibody for canine cancer, showed good tolerability in healthy dogs in a single‑ascending‑dose study, with doses up to three times the anticipated therapeutic level.
Inspired by human checkpoint inhibitors like Opdivo and Keytruda but built as a simpler biologic, BTC‑001 is being engineered for streamlined yeast‑based manufacturing and flexible dosing, as BioTesserae and Sunflower Therapeutics co-develop product formats and production methods on Sunflower’s scalable yeast platform to make next‑generation immuno‑oncology more affordable and accessible in veterinary practice.
Source: Businesswire
